Cationic and Biocompatible Polymer/Lipid Nanoparticles as Immunoadjuvants
Yunys Pérez-Betancourt,
Péricles Marques Araujo,
Bianca de Carvalho Lins Fernandes Távora,
Daniele Rodrigues Pereira,
Eliana Lima Faquim-Mauro,
Ana Maria Carmona-Ribeiro
Affiliations
Yunys Pérez-Betancourt
Biocolloids Laboratory, Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, Avenida Professor Lineu Prestes, 748 Butantan, São Paulo 05508-000, Brazil
Péricles Marques Araujo
Biocolloids Laboratory, Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, Avenida Professor Lineu Prestes, 748 Butantan, São Paulo 05508-000, Brazil
Bianca de Carvalho Lins Fernandes Távora
Immunopathology Laboratory, Butantan Institute, Avenida Vital Brasil, 1500 Butantan, São Paulo 05503-900, Brazil
Daniele Rodrigues Pereira
Immunopathology Laboratory, Butantan Institute, Avenida Vital Brasil, 1500 Butantan, São Paulo 05503-900, Brazil
Eliana Lima Faquim-Mauro
Immunopathology Laboratory, Butantan Institute, Avenida Vital Brasil, 1500 Butantan, São Paulo 05503-900, Brazil
Ana Maria Carmona-Ribeiro
Biocolloids Laboratory, Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, Avenida Professor Lineu Prestes, 748 Butantan, São Paulo 05508-000, Brazil
Nanostructures have been of paramount importance for developing immunoadjuvants. They must be cationic and non-cytotoxic, easily assembling with usually oppositely charged antigens such as proteins, haptens or nucleic acids for use in vaccines. We obtained optimal hybrid nanoparticles (NPs) from the biocompatible polymer poly(methyl methacrylate) (PMMA) and the cationic lipid dioctadecyl dimethyl ammonium bromide (DODAB) by emulsion polymerization of methyl methacrylate (MMA) in the presence of DODAB. NPs adsorbed ovalbumin (OVA) as a model antigen and we determined their adjuvant properties. Interestingly, they elicited high double immune responses of the cellular and humoral types overcoming the poor biocompatibility of DODAB-based adjuvants of the bilayer type. The results suggested that the novel adjuvant would be possibly of use in a variety of vaccines.
